Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases

Cardio-Cerebrovascular Disease is a collective term for cardiovascular disease and cerebrovascular disease, being a serious threat to human health. A growing number of studies have proved that the content of inflammatory factors or mediators determines the stability of vascular plaque and the incide...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 12; p. 745061
Main Authors Su, Jian-Hui, Luo, Meng-Yi, Liang, Na, Gong, Shao-Xin, Chen, Wei, Huang, Wen-Qian, Tian, Ying, Wang, Ai-Ping
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.08.2021
Subjects
atherosclerosis
IL-6Rα
inflammation
interleukin-6
ischemic stroke
Pharmacology
target
atherosclerosis
inflammation
IL-6Rα
interleukin-6
ischemic stroke
target
Online AccessGet full text

Cover

More Information
Summary:Cardio-Cerebrovascular Disease is a collective term for cardiovascular disease and cerebrovascular disease, being a serious threat to human health. A growing number of studies have proved that the content of inflammatory factors or mediators determines the stability of vascular plaque and the incidence of cardio-cerebrovascular event, and involves in the process of Cardio-Cerebrovascular Diseases. Interleukin-6 is a widely used cytokine that causes inflammation and oxidative stress, which would further result in cardiac and cerebral injury. The increased expression of interleukin-6 is closely related to atherosclerosis, myocardial infarction, heart failure and ischemic stroke. It is a key risk factor for these diseases by triggering inflammatory reaction and inducing other molecules release. Therefore, interleukin-6 may become a potential target for Cardio-Cerebrovascular Diseases in the future. This paper is aimed to discuss the expression changes and pathological mechanisms of interleukin-6 in Cardio-Cerebrovascular Diseases, and to provide a novel strategy for the prevention and treatment of Cardio-Cerebrovascular Diseases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by:Jun Peng, Jackpeng, China
These authors have contributed equally to this work and share first authorship
Duan-Fang Liao, Hunan University of Chinese Medicine, China
This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology
Edited by:Jian Gao, Shanghai Children’s Medical Center, China
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2021.745061